ESMO E-Learning: Clinical Cases in Breast Cancer (Triple Negative): Adherence to the ESMO Clinical Practice Guidelines
- To understand the biological, pathologic and clinical characteristics of triple-negative breast cancer.
- To understand the efficacy of cytotoxic agents and rationale for targeting therapy to specific phenotypic characteristics of triple-negative disease.
- To understand recently completed and ongoing research on novel targeted agents for the treatment of triple negative breast cancer.
This presentation has been developed with the purpose of discussing the clinical perspective of recently revised ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of breast cancer. The module consists of two particular patient cases with description of diagnosis, clinical scenario and treatment options in the adjuvant and metastatic setting of this challenging subtype of breast cancer.
Triple negative breast cancer accounts for approximately 15% of breast cancer cases. It is an immunohistochemically defined subtype of breast cancer that is negative for expression of oestrogen and progesterone receptors (ER/PR) and HER2. It is characterised by its unique molecular profile, aggressive behaviour, high rates of relapse, distinct patterns of metastasis and high prevalence among younger women. The poor prognosis, coupled with a lack of targeted use of therapies is reflected in the high mortality. In a minority of patients with highly chemosensitive disease, no robust clinical evidence exists to guide the use of current cytotoxics.
This E-Learning module includes cutting-edge information on cytotoxic and targeted agents. In order to provide practical information on optimised care of patients with triple-negative breast cancer, the emphasis is on putting data into a clinical context through case-based discussions focused on challenging treatment scenarios and controversies.
Critical to optimal future management is the accrual of adequately powered prospective trials to establish the treatment efficacy and define predictive biomarkers. This is the reason why in the current presentation many of the given options are not enough evidence-based yet.
Aiming to enhance experience with the ESMO Clinical Practice Guidelines material, we strongly recommend oncology professionals to refer to the full version of the guidelines text available in the May 2011 Supplement of the Annals of Oncology, as well as the Clinical Practice Guidelines section.
This E-Learning module was published in 2011 and expired in 2013.
The author has reported no conflicts of interest